Letermovir is being developed for human cytomegalovirus infection treatment and prophylaxis. In patients receiving transplants, antivirals are coadministered with cyclosporine A (CsA) or tacrolimus (TAC) immunosuppressants. Therefore, we investigated the potential for letermovir-immunosuppressant interactions. In 2 phase 1 clinical trials either CsA 50 mg or TAC 5 mg was administered to healthy males. Following washout, letermovir 80 mg was dosed twice daily for 7 and 11 days in the CsA and TAC trials, respectively, with a second dose of immunosuppressant coadministered with letermovir at steady state. In addition, letermovir 40 mg twice daily was administered for 14 days, and either CsA 50 or 200 mg administered on days 7 and 14. Pharmacokinetics and tolerability were assessed. Letermovir increased CsA and TAC C max by 37% and 70%, respectively, and exposure by 70% and 78%, respectively, compared with immunosuppressant alone; t ½ was also increased from 10.7 to 17.9 hours for CsA. CsA (50/200 mg) increased letermovir C max,ss (109%/167%) and AUC ss,τ (126%/237%) and decreased t ½ (4.33 to 3.68/3.04 hours) versus letermovir alone. TAC did not significantly affect letermovir pharmacokinetics. All treatments were well tolerated. Concomitant letermovir increased TAC and CsA exposure. CsA altered letermovir pharmacokinetics, whereas TAC did not.
Human cytomegalovirus (HCMV) infection remains highly prevalent, affecting ß50% of the US population and close to 100% of the population residing in countries with a developing economy. 1, 2 Typically, HCMV causes minimal morbidity in healthy subjects in primary infection and remains asymptomatic within the host. However, in immunocompromised individuals, such as those receiving bone marrow or solid-organ transplants, HCMV infection or reactivation can be life-threatening. 3 For example, in individuals receiving hematopoietic stem cell transplantation and without HCMV prophylaxis, HCMV disease historically develops in 20%-35% of cases. 4, 5 HCMV pneumonia, the most serious manifestation of the disease, subsequently results in mortality rates of 30%-50% in this patient population. [6] [7] [8] Because of the high prevalence and serious consequences of HCMV disease in the immunocompromised population, both preemptive and prophylactic therapies are indicated for patients receiving transplants. 5 Currently, ganciclovir or its prodrug valganciclovir are considered the standard treatments of choice to prevent HCMV disease. However, ganciclovir and other existing anti-HCMV treatments are associated with significant toxicity including but not limited to nephrotoxicity and bone marrow suppression, 9 -11 thus limiting their use in patients receiving stem cell transplants. In the example of ganciclovir, the drug targets viral polymerase enzymes and functions as a competitive inhibitor of deoxyguanosine triphosphate during viral replication. 12 However, the effects of polymerase inhibitors such as valganciclovir also often impact human polymerases, becoming a source of significant toxicity issues. 13, 14 Furthermore, polymerase inhibitors need to be activated inside infected cells by a viral kinase enzyme, therefore not offering protection in cells yet to be infected. Because of these considerable limitations, there remains a substantial unmet need for novel nonnucleoside HCMV treatments.
The requirement for new therapies led to the study of viral terminase inhibitors as a potential solution to the HCMV infection problem, [15] [16] [17] ultimately leading to the discovery of letermovir (MK-8228). 18 As the viral terminase complex has no mammalian counterpart, by targeting this enzyme it was expected that terminase inhibitors would demonstrate good tolerability. Like other terminase inhibitors, letermovir has been demonstrated to prevent the formation and release of infectious viral particles without the need for activation, thereby also protecting uninfected cells. [18] [19] [20] Recently, in a phase 3 clinical study in patients requiring stem cell transplantations (clinicaltrials.gov identifier: NCT02137772), letermovir reached the primary efficacy endpoint. As stem cell transplant recipients also require concomitant administration of immunosuppressive drugs, drug-drug interactions with letermovir were determined.
Immunosuppressant drugs for decreasing transplant rejection rates that are likely to be administered with letermovir include cyclosporine A (CsA) and tacrolimus (TAC). In vitro assays investigating the potential of letermovir to interact with drug-metabolizing enzymes and transporters that have been shown to impact the pharmacokinetics (PK) of CsA (CYP3A4/5, ABCB1, ABCC2, ABCG2, OATP1B1, and OATP1B3) and TAC (CYP3A4/5, ABCB1) indicated a potential for letermovir to interact with the 2 immunosuppressants. Further details of these in vitro methods and results can be found in the Supplementary Information section, including Supplementary Table 1. Both of these treatments are sensitive CYP3A4 substrates with a narrow therapeutic index and therefore prone to drug-drug interactions. 21 Based on in vitro data, there is a potential for letermovir to act as a weak irreversible inhibitor of CYP3A4, meaning that the effect of letermovir at steady state on the PK of single doses of CsA or TAC requires investigation. CsA metabolism is catalyzed by CYP3A4 in the liver and intestine, 22 and CsA can also inhibit transporters including OATP1B1, OATP1B3, P-gp, and breast cancer resistance protein (BCRP). [23] [24] [25] [26] Systemically available TAC is metabolized by hepatic CYP3A4 and CYP3A5 in the liver 27 and also demonstrates substantial gastrointestinal metabolism by CYP3A4. 28 TAC has been shown to inhibit other transporters such as BCRP, 26 with little to no effect on OATP1B1, 29 CYP3A4, or Pgp. 30 Because of the characteristics of both of these treatments, the potential for drug-drug interactions of CsA and TAC with letermovir via the oral administration route was investigated in healthy individuals.
Methods

Trial Design, Ethics, and Informed Consent
The current investigation comprised 2 phase 1 drugdrug interaction clinical trials. , and all subjects gave written informed consent.
In part 1 of the CsA trial, subjects received an oral dose of CsA (Sandimmun Optoral; Novartis GmbH) 50 mg on day 1; on days 3-9, letermovir 80 mg twice daily was administered, and a single oral dose of CsA 50 mg was given together with the morning dose of letermovir on day 9. For part 2 of the CsA trial, subjects were randomized 1:1 into 2 groups. The subjects were subsequently administered letermovir 40 mg twice daily on days 1-14 of the trial and CsA 50 or 200 mg, according to randomization group, on the mornings of days 7 and 14.
In the TAC trial, TAC (Prograf; Astellas Pharma) 5 mg was administered by mouth on day 1. On days 8-18, letermovir 80 mg twice daily was administered; in addition, TAC 5 mg was dosed on day 12.
Trial Population and Procedures
Healthy white male subjects, 18-45 years of age inclusive, with a normal body mass index (BMI) were eligible for inclusion in both clinical trials. Any subject who had experienced a previous reaction to the trial drugs was excluded. All treatments were an oral tablet, with letermovir given in the morning and evening under fasted states (10 hours in the morning prior to treatment administration and ß2-3 hours prior to evening dosing). Blood samples were collected at regular intervals In the CsA trial, the plasma concentrations of letermovir and CsA were determined by Bayer AG and the Analytical Department of FOCUS, respectively, both using validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The HPLC apparatus was an Agilent system 1100 with CTC-PAL autosampler. For letermovir, the analytical column was a Phenomenex Luna C8, 50 × 2 mm, 5 μM, with a Phenomenex Security Guard precolumn; the flow rate was 0.5 mL/min and the mobile phase was 100% acetonitrile. For CsA, the analytical column was a Phenomenex Luna CN 3μ, 50 × 4.6 mm, with a Phenomenex Luna CN precolumn; the flow rate was 1 mL/min and the mobile phase was 80% acetonitrile/20% 10 mM ammonium acetate (pH 3.0). The mass spectrometer for both analytes was an API 4000 (SCIEX) with TurboIonSpray (Applied Biosystems) set to the positive ion mode. The ionization voltage was set to 4.5 kV, and the detection mode was multiple reaction monitoring. The monitoring ions were set as m/z 1219.8 → 1202.7 for CsA and m/z 573.3 → 424.3 for letermovir. Both blank samples and blank samples spiked with either letermovir (0.1-200 μg/L) or CsA (0.989-203 ng/mL) were used to calibrate the assays. Prior to analysis of the plasma samples, chromatographic interference between CsA and letermovir was investigated using CsA dissolved in acetonitrile/ammonium acetate 10 mM (pH 3.0) 50/50 volume/volume. A concentration of 0.2 and 10 μg/L CsA did not cause a signal of the retention time of letermovir or the internal standard. For letermovir, mean interassay accuracy of back-calculated concentrations (except the lower limit of quantification [LLOQ]) in calibrators ranged from 95.7% to 106%, and precision was ࣘ4.74%. Accuracy and precision at the LLOQ were equal to 99.6% and 9.51%, respectively. Quality control samples in the concentration range from 0.300 to 2000 μg/L were determined with an accuracy of 89.8%-97.5% and a precision of 3.58%-8.86%.
The plasma concentrations of TAC and letermovir in the TAC trial were determined by the Analytical Department of FOCUS using samples in a validated HPLC-MS/MS method. The HPLC apparatus used to determine TAC concentrations was a Kontron HPLC pump system 522 with an HTC PAL autosampler (CTC analytics). The analytical column was a Phenomenex Luna CN 3μ, 50 × 4.6 mm, with a Phenomenex Luna CN precolumn; the flow rate was 1 mL/min and the mobile phase was 80% acetonitrile/20% 10 mM ammonium acetate. For the determination of letermovir concentrations, the HPLC apparatus was a MerckHitachi Pump 655 A-12 with a Perkin Elmer Series 200 autosampler (Perkin Elmer). The analytical column was a Phenomenex Luna 3μ C18, 50 × 3 mm, with a Phenomenex Luna 3μ C18, 4 × 4 mm precolumn; the flow rate was 0.7 mL/min and the mobile phase was 50% acetonitrile/50% 10 mM ammonium acetate (pH 4.0). The mass spectrometer for both analytes was a SCIEX API 3000 (SCIEX) with TurboIonSpray (Applied Biosystems) set to the positive ion mode and multiple reaction monitoring. The monitoring ions were set as m/z 821.7 → 768.7 for TAC and m/z 573.3 → 424.3 for letermovir. Stock solutions of TAC, sirolimus, and letermovir were prepared in methanol with subsequent dilutions for calibration, quality control, and internal standard samples made in acetonitrile/water (80:20) for TAC and sirolimus, and acetonitrile/10 mM ammonium acetate (pH 3.0) for letermovir. In the TAC trial, the calibration samples for TAC were prepared with concentrations of 0.470-101 ng/mL and quality control samples from 1.25 to 89.2 ng/mL. For letermovir, calibration samples of 5.07-2028 ng/mL and quality control samples of 14.6-1734 ng/mL were prepared. Accuracy of the back-calculated concentrations for TAC was 96.5%-106%, mean accuracy of the quality control samples was 95.4%-102%, and the corresponding precision data were 2.94%-5.89%. For letermovir, the accuracy of concentrations was 96.2%-104%, mean accuracy of the quality control samples was 99.3%-104%, and the corresponding precision data were 4.49%-4.96%.
In the CsA trial, calibration samples for CsA were prepared with concentrations of 0.986-203 ng/mL, whereas quality control samples had a range of 3.77-174 ng/mL. For letermovir, calibration samples of 0.1-200 ng/mL and quality control samples of 0.3-160 ng/mL were prepared. Accuracy of the backcalculated concentrations for CsA was 94.7%-107%, mean accuracy of the quality control samples was 100%-104%, and the corresponding precision data were 5.16%-6.10%. For letermovir, accuracy of backcalculated concentrations was 95.7%-106%, mean accuracy of the quality control samples was 91.2%-94.8%, and the corresponding precision data were 3.46%-8.86%. In the CsA trial, the LLOQ was 100 and 1 ng/mL for letermovir and CsA, respectively. In the TAC trial, the LLOQ was 5 and 0.5 ng/mL for letermovir and TAC, respectively. In both trials, values below this limit were set to "0."
PK Evaluations
In the CsA and TAC trials, area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC 0-Ý ), AUC from time zero until the time of the last measurable concentration (AUC 0-last ), maximum plasma concentration (C max ), time to C max (t max ), and apparent terminal half-life (t ½ ) for the immunosuppressive drugs were calculated. Letermovir AUC for a dosing interval of length τ at steady state (AUC ss,τ ), C max at steady state (C max,ss ), and t max at steady state within the dosing interval (t max,ss,τ ) were calculated in both trials.
Pharmacogenetics
To identify genetic causes of potential PK outliers, genotyping was performed on a range of alleles for drug-metabolizing enzymes and transporters (CYP3A4, CYP3A5, CYP2D6, CYP2C19, CYP2C9, P-gp, and uridine 5 -diphosphoglucuronosyltransferase 1-1) identified as potentially interacting with the trial drugs. Blood samples of 6 mL were drawn from each subject and sent to Epidauros Biotechnologie AG (Bernried, Germany) for genotyping. In both trials, DNA preparation and sequencing were performed using a method previously described in detail 31 with commercially available kits and ABI sequencing instruments (ABI 3730 or ABI 3130xl, all from Applied Biosystems).
Safety Assessments
Adverse events (AEs) were recorded throughout both trials and graded by severity. In addition, vital signs including heart rate, blood pressure, and pulse rate were measured, and physical examination, 12-lead electrocardiogram, and laboratory safety tests were also performed.
Data Analysis and Statistics
For the CsA trial, an investigation of "lack of interaction" was evaluated statistically using the same methods as a bioequivalence assessment. 32 The necessary sample size was governed by the intraindividual variation, which was reported for CsA to be 8.8% for AUC 0-Ý and 13.1% for C max . 33 Assuming a true ratio of 0.950 or 1.053 for with versus without coadministration of letermovir, a sample size of n = 10 completers was sufficient to allow a statistical proof of "lack of interaction" by the confidence interval (CI) inclusion rule with a probability (power) of 80%. 34 For the TAC trial, the determination of sample size was based on the 2-group paired t test at a level of 5%. The expected ratio of TAC administered with letermovir 80 mg twice daily (test) and administered alone on the logarithmic scale for AUC 0-Ý was assumed to be 1.35, and the coefficient of variation for the reference was assumed to be 30%. The size of the coefficient of variation was taken from another trial with TAC alone.
With a total sample size of 16 subjects, a 2-group (crossover) design would have 80% power to reject both null hypotheses that the ratio of the test mean to the reference mean was <0.5 and that the ratio of the test mean to the reference mean was >2.0, that is, that the test and reference were not equivalent, in favor of the alternative hypothesis that the means of the 2 groups were equivalent.
All subjects receiving treatment with the trial drugs who provided at least 1 assessment posttreatment were valid for inclusion in the safety analysis population. The PK analysis population included all subjects without major protocol deviations for whom plasma concentrations of the treatment drugs were available.
The PK variables of each drug were calculated using the WinNonlin program (version 5.0.1; Pharsight, Mountain View, California). To investigate the influence of letermovir on the PK parameters of CsA and TAC, an analysis of variance (including the factor "dosing day = treatment") was performed on the logtransformed values of the PK parameters AUC 0-Ý , AUC 0-last , and C max . Based on these analyses, point estimates (least-squares means) and 90%CIs for the ratio "analyte with letermovir/analyte alone" of the treatments were calculated by retransformation of the logarithmic data. If the 90%CIs for the ratios were fully included within the 80%-125% range, this was considered sufficient to conclude that there was no clinically relevant interaction of letermovir on the PK of the treatments.
Results
Trial Population
In the CsA trial, all 8 subjects completed part 1, and the mean age of participants ± standard deviation (SD) was 31.9 ± 8.1 years, with a mean BMI of 25.98 ± 3.29 kg/m 2 . In part 2 of the CsA trial, 11 of the 12 subjects completed the trial, 1 subject dropped out because of elevated liver enzymes, and an additional subject was lost to follow-up. Mean age ± SD of the participants in part 2 was 32.1 ± 7.5 years, and the mean BMI was 25.60 ± 1.98 kg/m 2 . Three of the 8 subjects in part 1 and 5 of the 12 subjects in part 2 were current smokers; 4 further subjects had smoked in the past, 2 in each part of the trial.
Two of the 16 subjects included in the TAC trial withdrew, 1 because of high liver enzymes and another because of the development of a urinary tract infection with prostatitis constituting a serious AE deemed by the investigators to be related to the immunosuppressive effects of TAC. Mean age ± SD of the subjects in the TAC trial was 36.1 ± 6.0 years, and the mean BMI of the subjects was 24.30 ± 2.44 kg/m 2 . Seven of the subjects were current smokers, and the other 9 had never smoked.
Effect of Letermovir on the Plasma PK of a Single Dose of CsA
The mean concentration-time profiles (Figure 1a) of CsA in the absence and presence of letermovir appeared to be similar in shape; however, the presence of letermovir increased levels of and prolonged exposure to CsA. These features were reflected in the PK characteristics of CsA under these conditions (Table 1) . When administered with letermovir, CsA C max increased by 37%, whereas median CsA t max was similar in both the presence and absence of letermovir. Despite the lack of difference in median t max , 3 of 8 subjects demonstrated an increase from 1.00-1.33 to 1.67-2.00 hours when in the presence of letermovir compared with its absence. Exposure to CsA, as demonstrated by the AUC values, was increased in the presence of letermovir by ß70% versus without letermovir, whereas the t ½ increased from 10.7 to 17.9 hours.
Effect of Letermovir on the Plasma PK of a Single Dose of TAC
Much like CsA, the mean concentration-time profiles for TAC in the absence and presence of letermovir were similar in shape. However, plasma concentrations of TAC were higher after steady-state administration of letermovir compared with administration of TAC alone (Figure 1b) . Furthermore, the concentration of TAC remained above detectable levels for longer in the presence of letermovir than it did without (120 vs 72 hours, respectively). The change in concentration-time profile was again seen in the PK characteristics of TAC in the absence and presence of letermovir (Table 1) . C max was increased by ß70% in the presence of concomitant letermovir compared with in its absence. In contrast, median t max was almost identical in both the presence and absence of letermovir. TAC exposure illustrated by the AUC 0-Ý values was increased by 78% in the presence of letermovir. Finally, TAC t ½ was similar both in the absence and the presence of letermovir. Within the TAC PK data, a single subject exhibited exceptionally low TAC plasma values after day 1 administration of TAC alone (C max of 3.74 ng/mL vs median C max on day 1 of 19.2 ng/mL). This increased 11-fold to 41.0 ng/mL after day 12 TAC and letermovir coadministration. No reason for the low blood concentration observed on day 1 was found, the subject was dosed under supervision of the investigator, and a mouth check was performed; in addition, no vomiting was reported.
Influence of Single-Dose CsA or TAC on Letermovir
The PK values for letermovir in all trials are shown in Table 2 for the CsA trial part 1, the CsA trial part 2, and the TAC trial. In addition, the concentration-time profiles for letermovir with and without coadministration of CsA and TAC can be seen in Figure 1 .
In part 1 of the CsA trial, the C max,ss of letermovir 80 mg twice daily increased by 72% and AUC ss,τ increased by 90% in the presence of CsA versus its absence. Letermovir 80 mg twice daily median t max,ss,τ was relatively unchanged by the presence or absence of CsA.
In part 2 of the CsA trial, letermovir 40 mg twice daily C max,ss was increased by 109% and 167% by the presence of CsA 50 and 200 mg, respectively, compared with in the absence of CsA. Meanwhile, t max,ss,τ was increased from 1 hour without CsA to 1.33 hours in the presence of both concentrations of CsA. Much like C max,ss , letermovir 40 mg twice daily AUC ss,τ was increased by 126% and 237% in the presence of CsA 50 and 200 mg, respectively, compared with letermovir alone.
The presence of TAC 5 mg decreased letermovir 80 mg twice daily C max,ss by ß8%, decreased median t max,ss,τ by 0.5 hours, and increased AUC ss,τ by 2% compared with in the absence of TAC. 
Pharmacogenetics
The pharmacogenetic measurements (data available on request) were performed to assess any outliers in the PK data. The low TAC plasma concentrations determined on day 1 for the outlying subject were not associated with any alleles known to alter TAC PK.
Safety
A complete list of AEs is shown in Table 3 . In part 1 of the CsA trial, 2 of 8 subjects (25%) reported a combined total of 4 AEs. The first subject had mild nausea and a mild headache after CsA alone and mild acute (10 minutes) renal pain 2 hours after the morning dose of letermovir alone. The subject had previously experienced this pain, and from a clinical perspective the origin appeared more likely to be muscular than renal. A second subject also experienced mild dizziness 1.5 hours prior to the morning dose of letermovir. All the AEs, with the exception of the headache, were considered treatment related. In part 2 of the CsA trial, 3 subjects reported treatment-related AEs after receiving letermovir alone. The first subject reported mild involuntary muscle contractions, and the second subject experienced mild tachycardia and elevated liver enzymes (alanine aminotransferase [ALT], 1.9 × the upper limit of normal [ULN]; glutamate dehydrogenase, 2.4 × ULN) that reached clinically significant values on the morning of day 7, leading to the withdrawal of the subject. Finally, the third subject experienced a mild headache 1.75 hours after dosing that lasted for 23 hours. After treatment with letermovir and CsA 50 mg, 2 subjects reported AEs considered related to treatment: a mild headache and mild palpitations. After treatment with letermovir and CsA 200 mg, 9 of 12 subjects (75%) experienced treatment-related AEs. Four subjects reported mild abdominal pain, 4 reported mild hot flashes, 3 experienced mild fatigue, a further 3 reported mild headaches, 1 had diarrhea, and 1 reported mild paresthesia. In the TAC trial, 5 of 16 subjects (31.3%) reported 19 AEs deemed to be related to treatment, 3 of which were related to TAC alone: dyspepsia, fatigue, and increase in hepatic enzymes. A further 9 treatment-related AEs were reported when letermovir was administered alone: vertigo, 2 occurrences of fatigue, malaise, pyrexia, urinary tract infection, headache, urethral pain, and prostatitis. Finally, 7 AEs occurred when letermovir was administered with TAC: blurred vision, upper abdominal pain, dyspepsia, nausea, arthralgia, and 2 occurrences of fatigue. When letermovir was administered alone, the AEs of fatigue, malaise, and prostatitis were associated with the subject who discontinued because of the urinary tract infection deemed by the investigators to be associated with the immunosuppressive effects of TAC. All the AEs in both trials resolved without sequelae. Clinically relevant changes in liver function parameters were observed in a single subject during the TAC trial, leading to the subject being withdrawn from the trial. The subject demonstrated increased ALT (79.2 U/L, 2.0-fold ULN) and glutamate dehydrogenase (14.8 U/L, 2.0-fold ULN) on day 8 of the trial, prior to the first dose of letermovir. Following the administration of letermovir on day 8 onward, ALT levels continued to rise until the subject was withdrawn from the trial on day 11, at which point ALT was 115.7 U/L (2.9-fold ULN). ALT levels then peaked 2 days after discontinuation (139.3 U/L, 3.5-fold ULN). After an additional 10 days, liver function parameters were within the normal range.
Discussion
These trials were conducted to identify interactions between letermovir and 2 sensitive CYP3A4 immunosuppressive drugs with a narrow therapeutic index commonly administered to patients receiving transplants. CsA undergoes extensive presystemic elimination and exhibits marked intestinal extraction. 35 Furthermore, CsA bioavailability can be altered by coadministration of CYP3A4 and P-gp inhibitors such as nelfinavir or indinavir. 36 Given the results of this trial, the effects of letermovir on CsA PK are likely to be explained by the inhibition of intestinal and hepatic CYP3A4 and/or P-gp. The presence of letermovir increased the C max of both CsA and TAC, whereas the t max of these immunosuppressive drugs was not affected, indicating that letermovir affected the extent but not the rate of CsA and TAC absorption. This suggests that letermovir interacted with the intestinal metabolism of CsA and TAC, but not with the transporters involved in CsA and TAC absorption. A clinical digoxin drug-drug interaction trial confirmed that the effect of letermovir on P-gp is weak and of limited clinical relevance, 37 further supporting the results of this trial. Furthermore, the AUC of both CsA and TAC increased. Interestingly, the t ½ of CsA was increased in the presence of letermovir compared with its absence, whereas the t ½ of TAC was not. This finding suggests that for CsA, letermovir increased the absorption and decreased first-pass elimination as well as CsA systemic clearance, whereas for TAC, only absorption was increased by reduction of first-pass elimination, leading to increased exposure.
During the TAC trial, a single subject demonstrated low PK values for TAC after day 1. The pharmacogenetic analysis did not identify any alleles associated with altered TAC PK, and the exposure at the second dose of TAC did not significantly differ from that of the other subjects. Therefore, although the subject denied having eaten before dosing on day 1, these extremely low plasma concentrations may suggest food intake, as TAC exhibits a marked negative food effect. 38 According to the classification criteria of the US Food and Drug Administration, and given the current results, letermovir is to be designated a weak inhibitor of CYP3A4 given its effect on CsA and TAC, 2 sensitive CYP3A4 substrates. 21 A secondary objective of both trials was to assess the influence of concomitant administration of the immunosuppressive drugs on the PK of letermovir. CsA 50 and 200 mg caused an increase in letermovir C max,ss and AUC ss,τ in a dose-dependent manner compared with letermovir alone. In contrast, concomitant dosing of TAC 5 mg and letermovir 80 mg twice daily versus letermovir alone had a minimal effect on letermovir PK. The change in letermovir PK observed in the presence of CsA is likely due to the inhibition of liver transporters, including ATP-binding cassette transporters and solute transporters, caused by CsA. 21 The lack of interaction of TAC in comparison with CsA has previously been observed with other drugs such as atorvastatin, 39 simvastatin, 40 and mycophenolic acid, 41 the latter of which also does not interact with letermovir. 42 The reduced interaction of TAC with such treatments compared with CsA has been previously ascribed to the inhibition of P-gp and enhancement of CYP3A4 activity associated with CsA. 39 An additional secondary objective was to assess the safety and tolerability of administering letermovir with CsA and TAC. The combined treatment of letermovir and CsA 50 or 200 mg was generally well tolerated, although the incidence of AEs was higher after coadministration of 200 mg CsA. The AEs associated with CsA administration (gastrointestinal disorders, hot flashes, headaches, and fatigue) have been previously reported. [43] [44] [45] Because these AEs are known for CsA and had a much lower incidence or were not observed after dosing letermovir alone or after coadministration with 50 mg CsA, it can be assumed that they were primarily related to the higher CsA dose.
In addition, repeated doses of letermovir 80 mg twice daily alone or in combination with TAC 5 mg were generally well tolerated. One subject presented serious AEs (urinary tract infection, prostatitis) on the second day of letermovir treatment. A relationship to letermovir was not considered likely; however, a triggering effect of TAC administration could not be excluded because of the immunosuppressive nature of the TAC dosed 10 days prior. The immunosuppressive effects of TAC have previously been identified as a potential risk factor for the development of urinary tract infections in kidney transplant patients. 46 However, in the current investigation, the length of time between the administration of TAC and the development of the infection means that caution must be taken when reaching this conclusion. An additional subject was excluded because of high liver enzymes. This increase started on day 8 before letermovir administration and therefore was not deemed to be caused by letermovir. However, the observed continued increase in liver enzymes after the start of letermovir dosing meant that an augmenting effect caused by letermovir could not be excluded.
In a recently completed phase 3 trial, letermovir was investigated at a dose of 480 mg once daily and 240 mg once daily with CsA, whereas in the investigations described here, subtherapeutic doses of letermovir were coadministered with the immunosuppressive drugs CsA and TAC. The low doses of letermovir were selected to ensure the safety of the healthy subjects, given the expected effect of this drug on CsA and TAC, both of which have a narrow therapeutic range. The findings of this trial suggest that although coadministration of letermovir and CsA or TAC influences the PK properties of these treatments, these combinations were generally well tolerated in healthy male subjects at the administered doses. However, the effect of low doses of letermovir on the PK of CsA and TAC, and the safety profile associated with its coadministration with these immunosuppressants, should be interpreted with caution, as the extent of drug-drug interaction might be greater at higher doses and a different safety profile might arise in a clinical population. The results of a previous phase 2 trial, in which patients received hematopoietic cell transplants, indicated that the combination of letermovir and TAC or CsA did not alter efficacy and demonstrated an acceptable safety profile. 47 However, in this previous study, the specific effects of each coadministered immunosuppressant were not assessed. The results presented here support reduced letermovir dosing (240 mg once daily versus 480 mg once daily) when CsA is concomitantly administered as immunosuppressive therapy. This regimen has been used in the completed phase 3 clinical trial, which will report efficacy and safety data at clinical doses in patients.
Conclusions
Concomitant letermovir 80 mg twice daily has a weak effect, as it increased CsA and TAC exposure in healthy subjects by less than 2-fold. The t ½ of CsA was increased by concomitant letermovir administration, whereas the t ½ of TAC was increased by a lesser amount. CsA increased letermovir exposure, but TAC did not. Both letermovir alone and letermovir with CsA or TAC were generally well tolerated in the healthy male subjects.
